Yes, sure. And I'll be happy. Hey, good morning, Andrew. Thanks for the question on that. So, yes, in the second quarter, as I was just answering Jeff's question, our healthcare business was impacted on the front-end of the revenue cycle management product offerings. So that's where predominantly what we're selling is insurance eligibility type of products, but we also have patient customization services and charity care and other identity products that we sell. The insurance eligibility was lower for the reasons that I just provided to Jeff just simply because the number of cases or patrons to come in, was significantly lower at the beginning of the second quarter. And as I said, it was all -- it was just the focus on COVID-19 for many providers, but we also -- we're dealing with patients kind of going to the hospitals for care, as well as too. As the quarter progressed, we did note that there was somewhat of a recovery on those preventative and elective procedures. And we've actually put out a couple of press releases, to kind of make that point throughout the quarter. So take a look at that, that's some good data that we put out in the market. What we saw on the back end of healthcare in the quarter is that the back end solutions were not down as much simply because of the reasons I just talked about on the front-end, hospital and other care providers, make the majority of the revenues, doing those preventative and elective care. When they shut down those procedures, it had a very significant impact on their operations. So with that, put them in a position unfortunately was to focus on their liquidity, which is where our back end revenue cycle management products came in to help them. And that part of our business, as you know, is focused on what we call insurance, coverage discovery, which is where we are looking for -- care that's been provided, but the provider has not been paid by a commercial insurer, or the government. So those, products service is actually slightly grew for us in the quarter, so that the net of it in Q2, I would -- as I said in my remarks held up relatively well, I'm not going to provide you the exact number but it wasn't a significant decline. I think we were very pleased with the results. As we think about the back half of the year. We are seeing as I said, a little bit of an uptick in the preventative and elective care, which is going to help the front end. But we're a little cautious about the back end right now, just simply because the volumes that weren't there in the April, May timeframe could potentially translate into lower revenues in the second half of the year.